Vistagen Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address unmet needs in the treatment of neuropsychiatric disorders
The company specializes in creating novel drug candidates that aim to improve the lives of patients suffering from conditions such as anxiety, depression, and other mood disorders. Through its unique platform, Vistagen is advancing treatments that target specific pathways in the brain, with the goal of offering safer and more effective alternatives to conventional therapies currently available in the market.
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQVTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQVTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).
Gainers SciSparc Ltd. (NASDAQSPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.
